What to consider before taking Bevacizumab
· Gena Health Team
Bevacizumab, is an antineoplastic, recombinant humanized monoclonal antibody belonging to the IgG1class is a widely used targeted therapy that inhibits vascular endothelial growth factor (VEGF), a protein essential for tumour blood vessel growth.
It is approved for several cancers, including ovarian, colorectal, lung, and glioblastoma (GBM). While bevacizumab can be effective in controlling disease progression for many patients, its benefits are not permanent. Over time, resistance can develop, and the drug may stop working. This means the cancer continues to progress despite ongoing treatment.
When this happens, it's understandable to feel uncertain. But progression on bevacizumab doesn't mean all options have been exhausted. Depending on your cancer type, stage, and treatment history, there are several next steps to consider - including switching therapies, exploring clinical trials, reassessing biomarkers, or focusing on supportive care.
This article explores different factors to consider before taking bevacizumab, and the alternative options patients may consider..
Understanding Bevacizumab and its role in cancer treatment
Cancer cells are highly adaptive. Over time, tumours can develop mechanisms to resist drugs. Bevacizumab works by binding to VEGF, blocking its interaction with receptors on blood vessel cells. This action starves tumours of the nutrients and oxygen they need to grow, helping to control cancer progression. In clinical practice bevacizumab is used as an immunotherapy in combination with chemotherapy or as maintenance therapy after initial treatment, depending on the cancer type.
The duration of response to bevacizumab varies depending on the cancer type and the clinical context. Some patients may benefit for several months, while others may see effects wane more quickly - sometimes as early as two months, but typically between two and eight months on average. In some clinical trials, the median duration of response for bevacizumab has been reported as approximately 5.3 months in certain cancer settings, such as recurrent glioblastoma, based on data from responder populations. The reason for this variation includes differences in tumour biology, genetic mutations, epigenetic factors and individual patient factors.
Why Bevacizumab may stop working
Cancer cells are highly adaptive. Over time, tumours can develop mechanisms to resist drugs such as bevacizumab, including activating alternative pathways to support blood vessel growth (such as FGF or PDGF), increasing their ability to invade surrounding tissues, or modifying the tumour environment to escape immune detection. These mechanisms can limit the drug's effectiveness and require oncologists to shift strategy.
Clinical considerations when Bevacizumab stops working
When bevacizumab is no longer effective, patients and their healthcare teams must reassess the treatment plan. Stopping bevacizumab can be challenging, as discontinuation may lead to a rebound effect, where symptoms or tumour growth accelerate.
This phenomenon has been observed in cancers such as ovarian cancer and glioblastoma, where rapid clinical deterioration, such as increased edema or tumour progression, may occur after cessation. This leads to reduced progression-free survival compared to standard treatments, underscoring the need for careful management during this transition off bevacizumab:
Monitoring and assessment
Regular Imaging and Biomarkers: Continued monitoring through imaging (CT, MRI) and tumour markers (e.g., CA125 in ovarian cancer) is crucial to detect progression early.
Symptom Management: Patients may require additional supportive care, such as steroids for edema or pain management, as symptoms can worsen upon discontinuation.
Ethical and psychological factors
Patient and Family Discussions: Open communication about the goals of care, potential benefits, and limitations of continued treatment is essential. Some patients may wish to continue therapy for psychological comfort, even if the clinical benefit is minimal.
Quality of Life: Balancing the desire for aggressive treatment with the risk of side effects and the impact on quality of life is a key consideration for both patients and clinicians.
Alternative treatment options to consider
When bevacizumab stops working, several alternative strategies may be considered, depending on the cancer type and individual patient factors.
1. Clinical trials
Participation in clinical trials is a valuable option for patients who have exhausted standard treatments. Trials may offer access to novel therapies, including new targeted agents, immunotherapies, or combination regimens and innovative technologies like tumour vaccines, bispecific antibodies, or cell therapies.
These studies offer access to cutting-edge therapies that are not yet widely available. Your oncologist or care team can help you search for suitable trials based on your diagnosis and treatment history. We can also support you through our research support service, helping you search for the latest research to identify relevant treatment options, clinical trials and emerging therapies.
2. Second-line chemotherapy or targeted therapies
Depending on the cancer type, second-line chemotherapy or targeted therapies may be recommended. For instance:
Ovarian Cancer: PARP inhibitors (e.g., olaparib, niraparib, rucaparib) are often used after bevacizumab, especially in patients with BRCA mutations or homologous recombination deficiency.
Lung Cancer: Options include pemetrexed, erlotinib, or docetaxel as second-line therapies.
Colorectal Cancer: Regimens may include irinotecan- or oxaliplatin-based chemotherapy, sometimes combined with other targeted agents.
Glioblastoma: Oncologists may consider re-irradiation, often alongside continued bevacizumab treatment. This strategy has shown survival benefit in some patients, particularly when other options are limited. Other options include lomustine (CCNU), temozolomide rechallenge, or investigational agents in clinical trials or expanded access programmes.
3. Reassessment and biomarker testing
If your cancer progresses, it may be possible to retest your tumour or blood for new mutations. Over time, cancers can evolve genetically, and biomarker testing may identify new targets for treatment. For example, next-generation sequencing (NGS) or liquid biopsy can uncover mutations in specific genes, potentially guiding the choice of subsequent therapies.
4. Supportive and palliative care
When curative options are exhausted, the focus may shift to palliative care to manage symptoms, improve quality of life, and provide psychological support. This approach is individualised and may include pain management, nutritional support, and counselling.
Key takeaways
Bevacizumab is effective for many patients but is not a cure; resistance and disease progression are common over time.
Stopping bevacizumab may lead to rebound effects, including accelerated tumour growth or worsening symptoms.
Alternative options may include enrolling in clinical trials, or starting second-line chemotherapy or targeted therapies.
Reassessment and Biomarker Testing may also be an option
Supportive and palliative care plays a vital role in managing symptoms and maintaining quality of life when curative options are exhausted.
Open communication with healthcare providers and consideration of patient preferences are essential throughout the treatment journey.
If you want to find out how we can help you identify an alternative treatment path please contact us here.
Medical Disclaimer: The information provided is for educational purposes only and should not substitute professional medical advice. Always consult healthcare professionals for medical decisions